Please provide your email address to receive an email when new articles are posted on . Results of a study showed that antirituximab antibodies are common among patients with pemphigus who have been ...

PARIS – September 9, 2021 – The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.

Please provide your email address to receive an email when new articles are posted on . Rituximab is associated with higher protection against long-term cardiovascular and metabolic diseases, but ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Significantly ...

Patients with pemphigus reported lower risk of myocardial infarction and stroke, among other cardiovascular and metabolic outcomes, when treated with rituximab compared with the first-line ...

Scientists at Scripps Research have reported success in initial tests of a new, nanotech-based strategy against autoimmune diseases. The National Institutes of Health has begun a clinical trial to ...

(RTTNews) - Sanofi (SNYNF, SNY) reported that its phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary ...

Controlled study to evaluate physical and psychosocial effects of a standardized in-patient rehabilitation program for patients after allogenic stem cell transplantation No significant financial ...